Antiproliferative effects of resveratrol and the mediating role of resveratrol targeting protein NQO2 in androgen receptor-positive, hormone-non-responsive CWR22Rv1 cells

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3011-3017

  Hsieh, Tze Chen ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

CWR22Rv1 cells; NQO2; Prostate cancer; Resveratrol

Indexed keywords

ANDROGEN RECEPTOR; DIHYDRONICOTINAMIDE RIBOSIDE QUINONE REDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL CYCLE ARREST; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; MALE; PROSTATIC NEOPLASMS; QUINONE REDUCTASES; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; STILBENES;

EID: 68549107732     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghom AD, Mehta RG, Moon RC and Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997. (Pubitemid 127696281)
2. Hsieh TC and Wu JM: Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249: 109-115, 1999.
3. Hsieh TC, Burfeind P, Laud K, Backer JM, Traganos F, Darzynkiewicz Z and Wu JM: Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int J Oncol 15: 245-252, 1999.
4. Kozuki Y, Miura Y and Yagasaki K: Resveratrol suppresses hepatoma cell invasion independently of its antiproliferative action. Cancer Lett 167: 151-156, 2001. (Pubitemid 32706677)
5. Miura D, Miura Y and Yagasaki K: Resveratrol inhibits hepatoma cell invasion by suppressing gene expression of hepatocyte growth factor via its reactive oxygen species-scavenging property. Clin Exp Metastasis 21: 445-451, 2004.
6. Tang FY, Su YC, Chen NC, Hsieh HS and Chen KS: Resveratrol inhibits migration and invasion of human breast cancer cells. Mol Nutr Food Res 52: 683-691, 2008.
7. Chen Y and Tseng SH: Review. Pro- and anti-angiogenesis effects of resveratrol. In Vivo 21: 365-370, 2007. (Pubitemid 46534292)
8. Belleri M, Ribatti D, Savio M, Stivala LA, Forti L, Tanghetti E, Alessi P, Coltrini D, Bugatti A, Mitola S, Nicoli S, Vannini V and Presta M: αvβ3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers. Mol Cancer Ther 7: 3761-3770, 2008.
9. Whitsett T, Carpenter M and Lamartiniere CA: Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog 5: 15, 2006. (Pubitemid 44150682)
10. Whitsett TG, Jr. and Lamartiniere CA: Genistein and resveratrol: mammary cancer chemoprevention and mechanisms of action in the rat. Expert Rev Anticancer Ther 6: 1699-1706, 2006. (Pubitemid 46062304)
11. Sengottuvelan M and Nalini N: Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br J Nutr 96: 145-153, 2006. (Pubitemid 44160908)
12. Sengottuvelan M, Viswanathan P and Nalini N: Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis 27: 1038-1046, 2006.
13. Wang Z, Hsieh TC, Zhang Z, Ma Y and Wu JM: Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun 323: 743-749, 2004. (Pubitemid 39243382)
14. Long DJ, 2nd and Jaiswal AK: NRH:quinone oxidoreductase2 (NQO2). Chem Biol Interact 129: 99-112, 2000.
15. Chen S, Wu K and Knox R: Structure-function studies of DT-diaphorase (NQO1) and NRH:quinone oxidoreductase (NQO2). Free Radic Biol Med 29: 276-284, 2000. (Pubitemid 30734911)
16. Knox RJ and Chen S: Quinone reductase-mediated nitroreduction: clinical applications. Methods Enzymol 382: 194-221, 2004.
17. Vella F, Ferry G, Delagrange P and Boutin JA: NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 71: 1-12, 2005. (Pubitemid 41715231)
18. Long DJ, 2nd, Iskander K, Gaikwad A, Arm M, Roop DR, Knox R, Barrios R and Jaiswal AK: Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 277: 46131-46139, 2002.
19. Iskander K, Paquet M, Brayton C and Jaiswal AK: Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res 64: 5925-5928, 2004. (Pubitemid 39129385)
20. Ahn KS, Gong X, Sethi G, Chaturvedi MM, Jaiswal AK and Aggarwal BB: Deficiency of NRH:quinone oxidoreductase 2 differentially regulates TNF signaling in keratinocytes: upregulation of apoptosis correlates with down-regulation of cell survival kinases. Cancer Res 67: 10004-10011, 2007. (Pubitemid 47621251)
21. Gong X, Kole L, Iskander K and Jaiswal AK: NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20S proteasomal degradation leading to stabilization and activation of p53. Cancer Res 67: 5380-5388, 2007. (Pubitemid 46997278)
22. DiPietrantonio AM, Hsieh TC and Wu JM: Specific processing of poly(ADP-ribose) polymerase, accompanied by activation of caspase-3 and elevation/reduction of ceramide/hydrogen peroxide levels, during induction of apoptosis in host HL-60 cells infected by the human granulocytic ehrlichiosis (HGE) agent. IUBMB Life 49: 49-55, 2000.
23. Hsieh TC, Kunicki J, Darzynkiewicz Z and Wu JM: Effects of extracts of Coriolus versicolor (I'm-Yunity) on cell-cycle progression and expression of interleukins-1 beta, -6, and -8 in promyelocytic HL-60 leukemic cells and mitogenically stimulated and nonstimulated human lymphocytes. J Altern Complement Med 8: 591-602, 2002. (Pubitemid 35291594)
24. Hsieh TC, Wu P, Park S and Wu JM: Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP). BMC Complement Altern Med 6: 30, 2006. (Pubitemid 44468828)
25. 1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int J Cancer 78: 53-61, 1998.
26. Darzynkiewicz Z, Bedner E and Smolewski P: Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol 38: 179-193, 2001. (Pubitemid 32319316)
27. Mgbonyebi OP, Russo J and Russo IH: Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12: 865-869, 1998. (Pubitemid 28133580)
28. Gehm BD, McAndrews JM, Chien PY and Jameson JL: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94: 14138-14143, 1997.
29. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983.
30. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21: 274-281, 1978. (Pubitemid 8283045)
31. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23, 1979. (Pubitemid 9239413)
32. Muraki J, Addonizio JC, Choudhury MS, Fischer J, Eshghi M, Davidian MM, Shapiro LR, Wilmot PL, Nagamatsu GR and Chiao JW: Establishment of new human prostatic cancer cell line (JCA-1). Urology 36: 79-84, 1990. (Pubitemid 20223256)